Trubion Pharma (TRBN) Granted Early Termination of HSR Waiting Period Related to Puchase by Emergent (EBS)
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that the U.S. Department of Justice and Federal Trade Commission granted the company early termination of its waiting period under the HSR Antitrust Improvements Act of 1976 , as amended, with respect to the planned acquisition of Trubion by Emergent BioSolutions Inc. (NYSE: EBS) announced on Aug. 12, 2010.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- BofA (BAC), Barclays (BCS) to Sell Remaining Archstone Interest in $1.58B Deal to Lehman Bros.
- BlackRock (BLK) Substantially Boosts Stake in Chesapeake (CHK) -CNBC's Kelly
- Delphi Automotive (DLPH) in Talks with FCI to Buy Motorized Vehicles Unit
Create E-mail Alert Related Categories
Corporate News, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
